

TNF

Research Grade Certolizumab

Catalog No.	DHB94401A DHB94401B	Quantity:	100 µg 1.0 mg
Alternate Names:	CDP870, PHA-738144, (Certolizumab pegol, CIMZIA)		
Description:	Certolizumab is a humanized monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha). It was developed as a humanized Fab fragment of 50 kDa, from an IgG1 isotype (without the Fc region) but is not pegylated. The absence of the Fc region was devised to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life (when pegylated) in the treatment of Crohn's disease and rheumatoid arthritis.		
Specificity:	Human TNF-alpha		
UniProt ID (target):	P01375		
Source:	XtenCHO cell line		
Isotype:	Humanized Fab'-G1 kappa		
Concentration:	1.0 mg/ml, lot specific		
INN:	Certolizumab		
Biologic Activity:	Neutralizing		
Endotoxin:	≤ 0.01 EU/µg by LAL analysis		
Formulation:	0.01M PBS, pH 7.4		
Purification:	Protein A or G affinity chromatography		
Purity:	> 95% as determined by SDS-PAGE		
Reactivity:	Human		
Applications:	Functional studies, ELISA		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

